Pharmaceutical Technology Europe, Jan 1, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology Europe, Jan 1, 2012
Editor's Comment
Go UK Bio
By Rich Whitworth
Firstly, Happy New Year! Please help yourself to a slice of cake.
Special Feature
Multilayer Tablets: A Piece Of Cake?
By Marcus Behrens , James Calvin , Doug Kirsch , LakshmiDevi Ethirajan
Multilayer tablets: A piece of cake or just a passing fad? We bring experts together to find out.
Multilayer Tablets: Critical Factors To Consider
By Vilayat A. Sayeed
Multilayer tablets can be challenging, but meeting regulatory expectations is crucial. We speak with Vilayat Sayeed from the FDA, to find out more about the critical factors that need to be fully understood.
Breaking The Mould
By David Beach
PTE interviews Accu-Break's David Beach about using multilayer technology to create accurate breakable tablets and flexible fixed-dose combination drugs.
Fixed-Dose Combinations
By Dr Ajay Gupta , Dr N. Udupa , Dr D. Sreedhar
Fixed-dose combinations (FDCs) reduce the number of pills that must be taken, but they have also been a topic of concern, mainly because of the perceived potential for increased adverse events. PTE speaks with researchers to explore the benefits and concerns of FDCs.
Industry Insider
European Pharma Companies Set To Surge Ahead Of US Rivals
By Nathan Jessop
The next two years may see a shake up in the world's current top pharmaceutical companies, with Pfizer likely to be the only US firm to remain in the top five by sales.
News
News
By Stephanie Sutton
The past few years have witnessed some dreary numbers in both Europe and the US when it comes to new products, but 2011 figures released by the European Medicines Agency may be early indicators for a 2012 upturn.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here